Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact The Gross Law Firm
12:55pm, Thursday, 01'st May 2025
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
June 3, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ABBV
05:45am, Thursday, 01'st May 2025
NEW YORK , May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV dur
Best Dividend Aristocrats For May 2025
08:07pm, Tuesday, 29'th Apr 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed
Final Trades: Netflix, Abbvie, iShares U.S. Industrials ETF and Sherwin Williams
01:33pm, Tuesday, 29'th Apr 2025
The Fast Money team just dropped their Final Trades — find out what's catching their eye now!
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a
Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next?
11:12am, Tuesday, 29'th Apr 2025
AbbVie Inc. ABBV is trading higher Tuesday. The stock has been in an uptrend.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Tuesday, 29'th Apr 2025
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Tuesday, 29'th Apr 2025
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
NEW YORK, NY / ACCESS Newswire / April 29, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the feder
RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
07:30am, Tuesday, 29'th Apr 2025
– RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults – Also known as temporal arteritis, GCA is the m
NEW YORK , April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a cl
Why AbbVie Stock Trounced the Market Today
07:02pm, Monday, 28'th Apr 2025
The positive, post-earnings momentum lifting AbbVie's (ABBV 3.57%) stock price continued on Monday. The veteran healthcare company's shares booked a gain of more than 3% during the trading session.
S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report
05:20pm, Monday, 28'th Apr 2025
Major U.S. equities indexes were mixed on the first day of a new trading week that will feature earnings reports from a slew of major corporations.
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
3 Dividend Stocks to Buy and Hold for the Next Decade
07:47am, Monday, 28'th Apr 2025
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
